QQQ   418.19 (-1.23%)
AAPL   164.99 (-1.23%)
MSFT   401.25 (-0.75%)
META   487.67 (-2.82%)
GOOGL   154.54 (-0.94%)
AMZN   176.26 (-1.65%)
TSLA   150.03 (+0.07%)
NVDA   817.75 (-3.42%)
AMD   149.59 (-3.54%)
NIO   3.86 (-3.50%)
BABA   68.89 (+0.01%)
T   16.29 (-0.24%)
F   12.09 (+0.25%)
MU   107.19 (-4.23%)
GE   150.22 (-1.78%)
CGC   7.68 (-1.92%)
DIS   111.75 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.77 (+1.50%)
PYPL   62.04 (-0.10%)
XOM   120.08 (+1.32%)
QQQ   418.19 (-1.23%)
AAPL   164.99 (-1.23%)
MSFT   401.25 (-0.75%)
META   487.67 (-2.82%)
GOOGL   154.54 (-0.94%)
AMZN   176.26 (-1.65%)
TSLA   150.03 (+0.07%)
NVDA   817.75 (-3.42%)
AMD   149.59 (-3.54%)
NIO   3.86 (-3.50%)
BABA   68.89 (+0.01%)
T   16.29 (-0.24%)
F   12.09 (+0.25%)
MU   107.19 (-4.23%)
GE   150.22 (-1.78%)
CGC   7.68 (-1.92%)
DIS   111.75 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.77 (+1.50%)
PYPL   62.04 (-0.10%)
XOM   120.08 (+1.32%)
QQQ   418.19 (-1.23%)
AAPL   164.99 (-1.23%)
MSFT   401.25 (-0.75%)
META   487.67 (-2.82%)
GOOGL   154.54 (-0.94%)
AMZN   176.26 (-1.65%)
TSLA   150.03 (+0.07%)
NVDA   817.75 (-3.42%)
AMD   149.59 (-3.54%)
NIO   3.86 (-3.50%)
BABA   68.89 (+0.01%)
T   16.29 (-0.24%)
F   12.09 (+0.25%)
MU   107.19 (-4.23%)
GE   150.22 (-1.78%)
CGC   7.68 (-1.92%)
DIS   111.75 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.77 (+1.50%)
PYPL   62.04 (-0.10%)
XOM   120.08 (+1.32%)
QQQ   418.19 (-1.23%)
AAPL   164.99 (-1.23%)
MSFT   401.25 (-0.75%)
META   487.67 (-2.82%)
GOOGL   154.54 (-0.94%)
AMZN   176.26 (-1.65%)
TSLA   150.03 (+0.07%)
NVDA   817.75 (-3.42%)
AMD   149.59 (-3.54%)
NIO   3.86 (-3.50%)
BABA   68.89 (+0.01%)
T   16.29 (-0.24%)
F   12.09 (+0.25%)
MU   107.19 (-4.23%)
GE   150.22 (-1.78%)
CGC   7.68 (-1.92%)
DIS   111.75 (-0.60%)
AMC   3.14 (+7.53%)
PFE   25.77 (+1.50%)
PYPL   62.04 (-0.10%)
XOM   120.08 (+1.32%)
NASDAQ:VERA

Vera Therapeutics (VERA) Stock Price, News & Analysis

$38.16
-1.32 (-3.34%)
(As of 11:34 AM ET)
Today's Range
$38.09
$40.34
50-Day Range
$37.41
$49.14
52-Week Range
$6.07
$50.78
Volume
334,506 shs
Average Volume
1.29 million shs
Market Capitalization
$2.08 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.29

Vera Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
19.3% Downside
$32.29 Price Target
Short Interest
Bearish
16.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.59mentions of Vera Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$21.53 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.26) to ($2.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.62 out of 5 stars

Medical Sector

861st out of 918 stocks

Pharmaceutical Preparations Industry

400th out of 426 stocks

VERA stock logo

About Vera Therapeutics Stock (NASDAQ:VERA)

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

VERA Stock Price History

VERA Stock News Headlines

2024's Must-Have Guide: Master Crypto Investment Today
The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
2024's Must-Have Guide: Master Crypto Investment Today
The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
Vera Therapeutics (NASDAQ:VERA) Sees Large Volume Increase
Vera Therapeutics: Waiting For A Pullback
Vera Therapeutics: Q4 Earnings Insights
VERA Mar 2024 17.500 call
VERA Apr 2024 40.000 call
See More Headlines
Receive VERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/20/2024
Today
4/19/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VERA
Fax
N/A
Employees
51
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.29
High Stock Price Target
$56.00
Low Stock Price Target
$22.00
Potential Upside/Downside
-18.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-95,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.94 per share

Miscellaneous

Free Float
42,636,000
Market Cap
$2.15 billion
Optionable
Optionable
Beta
1.05
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Sean P. Grant M.B.A. (Age 39)
    Chief Financial Officer
    Comp: $585.5k
  • Mr. Joseph R. Young M.B.A. (Age 51)
    Senior VP of Finance & Chief Accounting Officer
  • Mr. Julien E. Capers J.D.
    VP & Head of Legal
  • Ms. Kelly Rauber
    VP & Head of Human Resources
  • Mr. Tom Doan (Age 52)
    Senior Vice President of Development Operations
  • Ms. Lauren Frenz (Age 39)
    Chief Business Officer
  • Dr. Neeraj Pakala M.B.A.
    Ph.D., Senior VP and Head of Product Development & Manufacturing
  • Dr. Kerry Cooper M.D.
    Senior Vice President of Medical Affairs
  • Dr. Robert M. Brenner M.D. (Age 56)
    Chief Medical Officer
  • Mr. William D. Turner (Age 57)
    Chief Development Officer

VERA Stock Analysis - Frequently Asked Questions

Should I buy or sell Vera Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vera Therapeutics in the last twelve months. There are currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" VERA shares.
View VERA analyst ratings
or view top-rated stocks.

What is Vera Therapeutics' stock price target for 2024?

8 analysts have issued 1 year price objectives for Vera Therapeutics' shares. Their VERA share price targets range from $22.00 to $56.00. On average, they anticipate the company's share price to reach $32.29 in the next twelve months. This suggests that the stock has a possible downside of 19.3%.
View analysts price targets for VERA
or view top-rated stocks among Wall Street analysts.

How have VERA shares performed in 2024?

Vera Therapeutics' stock was trading at $15.38 at the beginning of 2024. Since then, VERA stock has increased by 160.1% and is now trading at $40.00.
View the best growth stocks for 2024 here
.

When is Vera Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VERA earnings forecast
.

How were Vera Therapeutics' earnings last quarter?

Vera Therapeutics, Inc. (NASDAQ:VERA) issued its quarterly earnings results on Wednesday, March, 20th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.05.

When did Vera Therapeutics IPO?

Vera Therapeutics (VERA) raised $66 million in an initial public offering (IPO) on Friday, May 14th 2021. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI acted as the underwriters for the IPO.

How do I buy shares of Vera Therapeutics?

Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VERA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners